Welcome to our dedicated page for Cardiol Therapeutics news (Ticker: $CRDL), a resource for investors and traders seeking the latest updates and insights on Cardiol Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cardiol Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cardiol Therapeutics's position in the market.
Rhea-AI Summary
Cardiol Therapeutics Inc. makes significant progress in 2023 and early 2024 with key developments in clinical trials and FDA designations. The company completed patient enrollment in the Phase II MAvERIC-Pilot study for recurrent pericarditis and exceeded 50% enrollment in the Phase II ARCHER trial for acute myocarditis. Topline results expected in Q2 2024. Cash and cash equivalents stand at $34.9 million, funding operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.73%
Tags
-
Rhea-AI Summary
Cardiol Therapeutics Inc. completes patient enrollment in Phase II study for CardiolRx™ in recurrent pericarditis, with topline results expected in Q2 2024. The study aims to inform a pivotal Phase III trial for potential regulatory approval, following Orphan Drug Designation by the FDA. Recurrent pericarditis, a debilitating heart disease, affects a significant number of patients in the US, leading to high healthcare costs and reduced quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.98%
Tags
-
Rhea-AI Summary
Cardiol Therapeutics Inc. receives Orphan Drug Designation from the FDA for its lead small molecule drug candidate, CardiolRx, aimed at treating recurrent pericarditis. The designation is based on pre-clinical and initial clinical data from the MAvERIC-Pilot Phase II study, highlighting the drug's potential to improve patients' lives. Recurrent pericarditis is a rare condition affecting around 38,000 patients annually in the US, with significant impact on quality of life and healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.31%
Tags
Rhea-AI Summary
Cardiol Therapeutics Inc. has announced that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This means that the Company is now in compliance with all applicable listing standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
-
Rhea-AI Summary
Cardiol Therapeutics Inc. (CRDL) exceeds 50% patient enrollment for ARCHER, a Phase II trial investigating CardiolRx™ for acute myocarditis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
-
Rhea-AI Summary
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is conducting MAvERIC-Pilot, a Phase II open-label pilot study investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis. The study, which has enrolled 50% of its 25-patient objective, is anticipated to complete patient recruitment during Q1 2024. The primary efficacy endpoint is the change in patient-reported pericarditis pain using an 11-point numeric rating scale, with secondary endpoints including the NRS score after 26 weeks of treatment and changes in circulating levels of C-reactive protein.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
Rhea-AI Summary
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced that study results demonstrated that cannabidiol treatment inhibits the mesothelial to mesenchymal transition in an experimental model of pericarditis. The results were presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. This research suggests a potential broader therapeutic benefit of CardiolRx™ in preventing pericarditis complications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
-
Rhea-AI Summary
Cardiol Therapeutics Inc. has achieved over 50% patient enrollment in its Phase II open-label pilot study investigating the safety and efficacy of CardiolRx in patients with recurrent pericarditis. The study aims to evaluate improvement in objective measures of the disease and the feasibility of reducing background therapy. The company expressed gratitude to clinical collaborators and patients for their contribution. Recurrent pericarditis is a debilitating inflammatory heart disease that affects quality of life and physical activity. The study will inform the design of a pivotal Phase III trial for potential regulatory approval of CardiolRx.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
-
Rhea-AI Summary
Cardiol Therapeutics receives notice of non-compliance with minimum bid price requirement on Nasdaq
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
Rhea-AI Summary
Results demonstrate that Cardiol's novel CRD-38 formulation attenuates harmful fat distribution and key markers of cardiac inflammation and remodelling. The study shows that subcutaneously administered cannabidiol slows increases in body weight and heart weight, and prevents increases in key cardiac inflammatory and remodelling markers in a model of heart failure with preserved ejection fraction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.23%
Tags
Cardiol Therapeutics Inc.
Nasdaq:CRDL
CRDL Rankings
CRDL Stock Data
135.17M
65.17M
3.96%
13.43%
0.5%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
Oakville
About CRDL
cardiol therapeutics is a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure. heart failure is a chronic condition that affects more than 26 million people globally. over five million adults in the u.s. suffer from heart failure, and it remains a leading cause of death and hospitalization with associated healthcare costs exceeding $30 billion annually. people with heart failure experience shortness of breath, fatigue, rapid heart rate, edema, reduced exercise capacity and a marked reduction in quality of life. approximately half of all heart failure patients have heart failure with preserved ejection fraction (hfpef), which is often associated with diabetes, obesity and high blood pressure and for which there have been no new therapies developed in over 20 years. cardiol is developing ctx01, a proprietary nanoformulation of pharmaceutical cannabidiol for the treatment of hfpef. cannabidiol has